title: Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?
abstract: The prevalence of resistant hypertension is seemingly much lower than had been reported in early studies. Recent analyses suggest that <5 % of treated hypertensive patients remain uncontrolled if fully adherent to an optimized antihypertensive treatment. However, these patients do have increased cardiovascular risk and need effective therapeutic approaches. Drug development is a high-risk, complex, lengthy, and very expensive process. In this article, we discuss the factors that should be considered in the process of developing a new agent for treatment of resistant hypertension.
authors.affiliation: Experimental Medicine CV/Hem, Clinical Sciences, Drug Discovery, Bayer Pharma AG, Aprather Weg 18a, Building 429, 42113, Wuppertal, Germany. eduardo.pimenta@bayer.com.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Pimenta
authors.affiliation: Sleep/Wake Disorders Center, Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.|Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Calhoun
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology; D004351:Drug Resistance; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology; D015995:Prevalence; D011379:Prognosis; D012307:Risk Factors
chemical_list: D000959:Antihypertensive Agents
keywords: Drug development; Refractory hypertension; Resistant hypertension